mTORC1 promotes survival through translational control of Mcl-1
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E μ- myc murine lymphoma model leads to mTORC1 activation and accelerated oncogenesis caused by a defective apoptotic program despite compromised AKT phosphorylation. Tumors from Tsc2 +/− E μ- Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin. We identified myeloid cell leukemia sequence 1 ( Mcl-1 ), a bcl-2 like family member, as a translationally regulated genetic determinant of mTORC1-dependent survival. Our results indicate that the extent by which rapamycin can modulate expression of Mcl-1 is an important feature of the rapamycin response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TORC1 inhibition, via loss of 4EBP1 (also referred to as EIF4EBP1) phosphorylation, results in a decrease of MCL-1 protein expression in these cancers (37–40).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous studies had demonstrated that efficient translation of MCL-1 mRNA requires cap-dependent translation in some cancers (36–38).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citation
Cited by
Items 101–200 of 285
Nifoussi, S. K., Vrana, J. A., Domina, A. M., Biasio, A. D., Gui, J., Gregory, M. A., Hann, S., & Craig, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047060 · Cited by 53
Translation initiation: a critical signalling node in cancer
Robert, F., & Pelletier, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903241625 · Cited by 48
“Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-”
BackgroundInfluentialSelf-citationBcl-2 family proteins, beyond the veil
Glab, J., Cao, Z., & Puthalakath, H. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2019.12.001 · Cited by 52
Huye, L. E., Nakazawa, Y., Patel, M. P., Yvon, E. S., Sun, J., Savoldo, B., Wilson, M. H., Dotti, G., & Rooney, C. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.179 · Cited by 49
Müller, A., Zang, C., Chumduri, C., Dörken, B., Daniel, P. T., & Scholz, C. W. (2013) · International Journal of Cancer · doi:10.1002/ijc.28206 · Cited by 46
“As dephosphorylation of GSK3b induces its activation and active GSK3b designates Mcl-1 for ubiquitination, leading to proteasomal degradation,13 this may also influence the expression of Mcl-1.”
BackgroundResultInfluentialLaukkanen, S., Veloso, A. B., Yan, C., Oksa, L., Alpert, E. J., Do, D., Hyvärinen, N., McCarthy, K. M., Adhikari, A., Yang, Q., et al. (2022) · Blood · doi:10.1182/blood.2021015106 · Cited by 48
Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death
Bock, F. J., Sedov, E., Koren, E., Koessinger, A. L., Cloix, C., Zerbst, D., Athineos, D., Anand, J., Campbell, K. J., Blyth, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26613-0 · Cited by 54
Spender, L. C., & Inman, G. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0394 · Cited by 45
“Both c-MYC and MCL-1 (48) are regulated at the level of protein stability because their half-life is short.”
BackgroundFalco, F. D., Sabatini, R., Papa, B. D., Falzetti, F., Ianni, M. D., Sportoletti, P., Baldoni, S., Screpanti, I., Marconi, P., & Rosati, E. (2015) · Oncotarget · doi:10.18632/oncotarget.4116 · Cited by 55
“Mcl-1 protein expression is regulated at multiple levels, including transcription, translation and degradation [26-31].”
BackgroundTargeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 46
“Previous reports have shown that MCL-1 protein expression is regulated by cap-dependent translation 27,28 .”
Li, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 43
Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
Jin, H.-O., HONG, S. I., Woo, S.-H., Lee, J.-H., Choe, T.-B., Kim, E.-K., Noh, W.-C., Lee, J.-K., Hong, S.-I., Kim, J. M., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.63 · Cited by 43
“50 untranslated region among the antiapoptotic Bcl-2 members.19,27,28 In addition, inhibition of mTOR with rapamycin blocked Mcl-1 protein synthesis, but not that of Bcl-2 or Bcl-xL.19 Surprisingly, knockdown of Twist1 led to a marked increase in the ADP/ATP ratio, indicating a decrease in ATP content.”
BackgroundInfluentialTherapeutic Opportunities in Eukaryotic Translation
Chu, J., & Pelletier, J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032995 · Cited by 47
“…(e.g., c-MYC, cyclins, ornithine decarboxylase [ODC], BCL-2, MCL-1, BCL-XL, osteopontin, survivin, vascular endothelial growth factor [VEGF], fibroblast growth factors [FGF]) (Colina et al. 2008; Mills et al. 2008; Petroulakis et al. 2009; Dowling et al. 2010; Bhat et al. 2015; Chu et al. 2016a).”
BackgroundSelf-citationBommer, U., Iadevaia, V., Chen, J., Knoch, B., Engel, M., & Proud, C. G. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.011 · Cited by 42
“We also found previously that downregulation of TCTP may occur at the translational level, through activation of protein kinase PKR [54, 70], a mechanism similarly reported for Mcl-1 [71].”
BackgroundInfluentialMultiple components of the spliceosome regulate Mcl1 activity in neuroblastoma
Laetsch, T. W., Liu, X., Vu, A. T., Sliozberg, M., Vido, M. J., Elci, O. U., Goldsmith, K. C., & Hogarty, M. D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.40 · Cited by 40
“The mechanisms for this in NB require further studies but may include reduced recruitment of mTORC1 to the pre-mRNA, which has been linked to decreased translation.(40,41) Our work identifies spliceosome inhibition as a potential therapeutic target to antagonize Mcl1 in NB.”
BackgroundSilibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1152 · Cited by 42
“Treatment of cells with silibinin has also been shown to inhibit expression of Mcl-1 and survivin (23, 24), two eIF4E-responsive genes (25, 26).”
BackgroundSelf-citationTang, Y., Yang, Y., Luo, J., Liu, S., Zhan, Y., Zang, H., Zheng, H., Zhang, Y., Feng, J., Fan, S., et al. (2020) · Cancer Biomarkers · doi:10.3233/cbm-200410 · Cited by 40
“On one hand, as a highly unstable protein, Mcl-1 is very sensitive to activity of mechanistic target of rapamycin complex 1 (mTORC1)-dependent translation [39,40].”
BackgroundRobert, F., Mills, J. R., Agenor, A., Wang, D., Marco, S. D., Cencic, R., Tremblay, M. L., Gallouzi, I., Hekimi, S., Wing, S. S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2739 · Cited by 38
“In the Em-Myc lymphomamodel, whereMyc overexpression is driven by the lymphoid-specific IgH enhancer (Em) in the preB/B-cell compartment (13), lesions in the Akt-Tsc1/2 pathway accelerate lymphomagenesis (11, 14).”
BackgroundMethodSelf-citationKinetic Heterogeneity of Cancer Cell Fractional Killing
Inde, Z., Forcina, G. C., Denton, K., & Dixon, S. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107845 · Cited by 39
Lindquist, R. A., Ottina, K. A., Wheeler, D. B., Hsu, P. P., Thoreen, C. C., Guertin, D. A., Ali, S. M., Sengupta, S., Shaul, Y. D., Lamprecht, M. R., et al. (2011) · Genome Research · doi:10.1101/gr.111492.110 · Cited by 44
“2010), and that in such conditions, acute rapamycin treatment can reduce translation of anti-apoptotic proteins (Mills et al. 2008; Bhaskar et al. 2009).”
BackgroundCombined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50063-z · Cited by 41
“MCL-1 translation has previously been shown to be mTOR dependent 27,28 .”
BackgroundZheng, L., Yang, W., Zhang, C., Ding, W., Zhu, H., Lin, N.-M., Wu, H., He, Q., & Yang, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.011 · Cited by 41
“mTORC1 (mTOR complex 1), one downstream target in PI3 K/Akt pathway, could promote survival through translational control of Mcl-1 [28].”
BackgroundChoi, H.-N., Jin, H., Kim, J., Hong, S., Kim, H., Kim, E., Lee, J. K., Park, I., & Noh, W. C. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.074 · Cited by 38
Zhang, W., Ruvolo, V. R., Chen, G., Zhou, L., Bornmann, W. G., Tsao, T., Schober, W. D., Smith, P. D., Guichard, S. M., Konopleva, M. Y., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0576 · Cited by 38
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors
Katigbak, A., Cencic, R., Robert, F., Sénécha, P., Scuoppo, C., & Pelletier, J. (2016) · Scientific Reports · doi:10.1038/srep38968 · Cited by 45
“This model has correctly reported on the ability of p53 suppression 37 or Tsc1 and Tsc2 loss 15 to accelerate tumorigenesis - genes mutated in human BL.”
Self-citationPI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity
Schülein‐Völk, C., Eilers, M., & Popov, N. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.036 · Cited by 44
Okada, K., Nogami, A., Ishida, S., Akiyama, H., Chen, C., Umezawa, Y., & Miura, O. (2017) · Oncotarget · doi:10.18632/oncotarget.22926 · Cited by 38
“We next performed the pull-down assays using m7-GTP beads to evaluate the effect of AZD1208 and GDC-0941 on formation of the eIF4E/eIF4G complex, which enhances the cap-dependent translation of mRNAs having lengthy, G+C-rich, highly structured 5’-UTRs, such as Mcl-1 mRNA [15].”
MethodWarr, M. R., Mills, J. R., Nguyen, M., Lemaire‐Ewing, S., Baardsnes, J., Sun, K. L. W., Malina, A., Young, J. C., Jeyaraju, D. V., O'Connor‐McCourt, M. D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.218321 · Cited by 37
Self-citationThe dynamics and regulation of microfilament during spermatogenesis
Yang, T., & Yang, W.-X. (2020) · Gene · doi:10.1016/j.gene.2020.144635 · Cited by 37
mTOR as a senescence manipulation target: A forked road
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2021.02.002 · Cited by 35
Dunn, S., Eberlein, C., Yu, J., Gris‐Oliver, A., Ong, S. H., Yelland, U., Cureton, N., Staniszewska, A. D., McEwen, R. K., Fox, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02482-9 · Cited by 43
“For example the PI3K/AKT pathway controls phosphorylation of Bad and downregulates Mcl-1 expression [40, 41].”
BackgroundMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies
Sionov, R. V. (2013) · ISRN Hematology · doi:10.1155/2013/348212 · Cited by 37
“In an Akt-driven, Eμμ-Myc lymphoma mouse model, translational regulation of Mcl-1 by mTOR has been implicated in promoting lymphomagenesis [377].”
BackgroundZhang, L., Liu, G., Kong, M., Li, J., Wu, D., Zhou, X., Yang, C., Xia, L., Yang, Z., & Chen, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz542 · Cited by 34
Demosthenous, C., Han, J., Stenson, M. J., Maurer, M. J., Wellik, L. E., Link, B. K., Hege, K. M., Doǧan, A., Sotomayor, E. M., Witzig, T. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3378 · Cited by 35
“Decreased translational efficiency of Mcl-1 mRNA after rapamycin treatment has also been shown before.[33] In summary, this study presents information regarding alterations in the translation control providing, in parallel, a mechanistic basis of targeting cap-dependent translation through next generation mTORC1/mTORC…”
MCL-1 is a clinically targetable vulnerability in breast cancer
Winder, M. L., & Campbell, K. J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2054096 · Cited by 38
“MCL-1 is a particularly short-lived protein (estimated half life ~1–3 hours) and MCL1 mRNA is considered “weak” due to its GC-rich and highly structured 5’ untranslated region (UTR) [64,65].”
BackgroundLiu, L., Kritsanida, M., Magiatis, P., Gaboriaud‐Kolar, N., Wang, Y., Wu, J., Buettner, R., Yang, F., Nam, S., Skaltsounis, A., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21781 · Cited by 35
“These proteins are regulated by Akt and/or STAT3 signaling.(10,24,25,34,35) We analyzed expression levels of these apoptosis-related proteins in four human melanoma cell lines by Western blotting analysis (Fig.”
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradationviaMule in colorectal cancer cells
Park, S. H., Lee, D.-H., Kim, J. L., Kim, B. R., Na, Y. J., Jo, M. J., Jeong, Y. A., Lee, S., Lee, S. I., Lee, Y. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11147 · Cited by 34
“Even though Mcl-1 potentially could be controlled at multiple levels [60, 61], metformin did not affect the transcriptional level, protein stability, or degradation of Mcl-1 in CRC cells, indicating that the metformin-induced decrease of Mcl-1 protein was not because of transcriptional or post-translational regulation.”
BackgroundAutophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
Al‐Odat, O. S., Guirguis, D. A., Schmalbach, N. K., Yao, G., Budak-Alpdoǧan, T., Jonnalagadda, S. C., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010644 · Cited by 40
Sasi, B. K., Martines, C., Xerxa, E., Porro, F., Kalkan, H., Fazio, R., Turkalj, S., Bojnik, E., Pyrzyńska, B., Stachura, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0442-8 · Cited by 36
Through a glass less darkly: apoptosis and the germinal center response to antigen
Peperzak, V., Vikstrom, I. B., & Tarlinton, D. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01123.x · Cited by 37
“Rapamycin induced blockade of mTOR, downstream of PI3K ⁄ AKT, also results in decreased stability of Mcl-1 (86).”
BackgroundRNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model
Mills, J. R., Malina, A., Lee, T., Paola, D. D., Larsson, O. S., Miething, C., Große, F., Tang, H., Zannis‐Hadjopoulos, M., Lowe, S. W., et al. (2013) · Blood · doi:10.1182/blood-2012-06-434365 · Cited by 36
“To confirm that resistance to ABT-737 could be conferred by endogenous Mcl-1 in ArfEm-myc/Bcl-2 cells, we inhibited Mcl-1 expression with either RNAi or using the translation inhibitor cycloheximide (CHX)— conditions that dramatically reduce MCL-1 protein levels and elicit apoptosis in parental ArfEm-myc lymphomas (su…”
MethodSelf-citationRahmani, M., Aust, M. M., Hawkins, E., Parker, R. E., Ross, M., Kmieciak, M., Reshko, L. B., Rizzo, K., Dumur, C. I., Ferreira‐Gonzalez, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.130351 · Cited by 32
“Translation of the short-lived protein Mcl-1 is regulated by mTORC1.(41) The observation that INK128 significantly down-regulated Mcl-1, but rapamycin exerted only modest effects, suggests that factors other than mTORC1 contribute to the marked Mcl-1 down-regulation, at least in some cell types.”
BackgroundMechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Tantawy, S. I., Sarkar, A., Hubner, S., Tan, Z., Wierda, W. G., Eldeib, A., Zhang, S., Kornblau, S., & Gandhi, V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2088 · Cited by 34
Domostegui, A., Peddigari, S., Mercer, C. A., Iannizzotto, F., Rodríguez, M. L., Garcia‐Cajide, M., Amador, V., Diepstraten, S. T., Kelly, G. L., Salazar, R., et al. (2021) · Blood · doi:10.1182/blood.2020007452 · Cited by 36
Self-citationJung, H. R., Oh, Y., Na, D., Min, S., Kang, J., Jang, D., Shin, S., Kim, J., Lee, S. E., Jeong, E. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01777-7 · Cited by 31
“Previous study showed that mTOR signaling positively regulate the translation of MCL1 [44].”
BackgroundResistance to HSP90 inhibition involving loss of MCL1 addiction
Busacca, S., Law, E. W. P., Powley, I. R., Proia, D. A., Sequeira, M., Quesne, J. P. C. L., Klabatsa, A., Edwards, J. M., Matchett, K. B., Luo, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.213 · Cited by 29
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice
Chen, J., Zhang, X. D., & Proud, C. G. (2015) · Science Signaling · doi:10.1126/scisignal.aac8321 · Cited by 30
Hong, S., Kim, E., Jin, H., Kim, H., Lee, J. K., Koh, J. S., Seol, H., Kim, J., Park, I., & Noh, W. C. (2013) · Cell Biology and Toxicology · doi:10.1007/s10565-013-9253-2 · Cited by 30
“PF4708671 downregulates the expression levels of Mcl-1 and survivin Recently, several studies reported thatMcl-1 and survivin expression is downregulated through a posttranscriptional mechanism mediated via blocking mTORC1/S6K1 signaling (Kim et al. 2011a, b; Mills et al. 2008; Choi et al. 2013).”
BackgroundBonnefond, M.-L., Lambert, B., Giffard, F., Abeilard, E., Brotin, É., Louis, M.-H., Gueye, M. S., Gauduchon, P., Poulain, L., & N’Diaye, M. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1095-3 · Cited by 31
“also known to regulate Mcl-1 translation focusing research to target this network in order to sensitize cancer cells [19].”
BackgroundLee, J. S., Tang, S. S. K., Ortiz, V., Vo, T.-T. T., & Fruman, D. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6051 · Cited by 33
“It is important to note that dysregulated MCL-1 expression can be conferred by defects in any of the multiple layers of regulation (transcriptional [42, 53], translational [52], and post-translational levels [54-56]).”
Vervloessem, T., Sasi, B. K., Xerxa, E., Karamanou, S., Kale, J., Rovere, R. M. L. L., Chakraborty, S., Sneyers, F., Vogler, M., Economou, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02944-6 · Cited by 33
Ye, H., Liu, Y., Wu, K., Luo, H., & Cui, L. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00584-z · Cited by 27
Bhat, M., Yanagiya, A., Graber, T. E., Razumilava, N., Bronk, S. F., Zammit, D., Zhao, Y., Zakaria, C., Metrakos, P. P., Pollak, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10671 · Cited by 29
“Staining for the anti-apoptotic protein Mcl-1, whose expression was shown to be regulated by mTORC1 [35], revealed that there was a significant decrease in Mcl-1 positive cells in nodules of metformin-treated mice as compared to those from mice injected with vehicle alone (p<0.”
BackgroundInfluentialvan Attekum, M. H. A., Terpstra, S., Slinger, E., Lindern, M. V., Moerland, P. D., Jongejan, A., Kater, A. P., & Eldering, E. (2017) · Oncogene · doi:10.1038/onc.2016.515 · Cited by 28
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
Torrealba, N., Rodríguez‐Berriguete, G., Fraile, B., Olmedilla, G., Martínez-Onsurbe, P., Sánchez‐Chapado, M., Paniagua, R., & Royuela, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1424130 · Cited by 28
“MTORC1 is known as regulator in the translation of Mcl-1, which contributes to mTORC1 dependent survival [20].”
BackgroundFisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells
Lim, J. Y., Lee, J. Y., Byun, B. J., & Kim, S. H. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.07.004 · Cited by 26
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Williams, M. M., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V. M., & Cook, R. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27070 · Cited by 29
“Increased cap-dependent translation of MCL1, particularly under conditions of cellular stress, reportedly contributes to Mcl-1 protein upregulation [18, 19].”
BackgroundLiu, X., Lv, Z., Zou, J., Liu, X., Ma, J., Wang, J., Sa, N., Jing, P., & Xu, W. (2016) · Europe PMC (PubMed Central) · Cited by 38
Genome-wide search for exonic variants affecting translational efficiency
Li, Q., Makri, A., Lu, Y. Z., Marchand, L., Grabs, R., Rousseau, M., Ounissi‐Benkalha, H., Pelletier, J., Robert, F., Harmsen, E., et al. (2013) · Nature Communications · doi:10.1038/ncomms3260 · Cited by 29
Self-citationBuqué, A., Aresti, U., Calvo, B., Jangi, M., Múñoz, A., Carrera, S., Azkona, E., Rubio, I., & López-Vivanco, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063338 · Cited by 25
“Active Akt is able to regulate several molecules involved in cell survival, both directly and indirectly, through mammalian target of rapamycin (mTOR) which is responsible for controlling the cell cycle, apoptosis and growth via the regulation of several downstream proteins [4–10].”
BackgroundEukaryotic cell survival mechanisms: Disease relevance and therapeutic intervention
Twayana, K. S., & Ravanan, P. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.05.002 · Cited by 29
Li, X., Li, B., Ni, Z., Zhou, P., Wang, B., He, J., Xiong, H., Yang, F., Wu, Y., Lyu, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0763 · Cited by 24
“Previous reports have shown that the translation of MCL-1 and survivin is regulated in the mTORC1mediated cap-dependentmanner (19, 20).”
BackgroundMalvi, P., Chava, S., Cai, G., Hu, K., Zhu, L. J., Edwards, Y. J. K., Green, M. R., Gupta, R., & Wajapeyee, N. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101285 · Cited by 26
“57 Thus, the increase in apoptosis, potentially via reduction in MCL1 levels, may in part contribute to the increased efficacy of combination therapy.”
BackgroundPleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis
Hoshii, T., Matsuda, S., & Hirao, A. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu037 · Cited by 28
Bonnefond, M.-L., Florent, R., Lenoir, S., Lambert, B., Abeilard, E., Giffard, F., Louis, M.-H., Elie, N., Briand, M., Vivien, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26084 · Cited by 24
“The Mcl-1 down-regulation we evidenced may be attributed to translational events, as CAI strongly repressed P-4EBP1, which is known to control Mcl-1 protein expression [11, 12].”
BackgroundCho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0735 · Cited by 24
“Inhibition of mTOR pathway by combination treatment of ABT-263 and YM-155 To investigate whether downregulation of MCL1 is due to decreased MCL1 protein synthesis, we evaluated three proteins, S6K, eIF4E-binding protein 1 (4EBP1), and AKT, that are in the mTOR pathway, which regulates protein translation of MCL1 (31).”
MethodChiang, C.-T., Yeh, P.-Y., Gao, M., Chen, C.-W. D., Yeh, L.-C., Feng, W.-C., Kuo, S., Hsu, C., Lu, Y., & Cheng, A. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.005 · Cited by 23
“Mcl-1 is a key regulatory protein that couples cell survival to translational regulation [30], and treatment with mTOR inhibitor lead to reduced Mcl-1 expression in several hematological malignant cells [31] and HER2-amplified breast cancers [32].”
BackgroundTailler, M., Lindqvist, L., Gibson, L., & Adams, J. M. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0244-y · Cited by 23
Physiological Functions of Mcl-1: Insights From Genetic Mouse Models
Chin, H. S., & Fu, N. Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.704547 · Cited by 22
“Moreover, the abundance of Mcl-1 protein can be tightly controlled through the translational regulation of Mcl-1 mRNA by the mTOR pathway (Mills et al., 2008; Coloff et al., 2011; Fu et al., 2015).”
BackgroundAntagonistic role of natural compounds in mTOR-mediated metabolic reprogramming
Cerella, C., Gaigneaux, A., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.008 · Cited by 26
Hypergrowth mTORC1 Signals Translationally Activate the ARF Tumor Suppressor Checkpoint
Miceli, A. P., Saporita, A. J., & Weber, J. D. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06030-11 · Cited by 23
“Additionally, mTORC1 signaling has been reported to specifically modulate the translation of myeloid cell leukemia sequence 1 (Mcl-1) (32).”
BackgroundRegulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2
Basu, A., & Sridharan, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173854 · Cited by 24
Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition
Mattoo, A. R., Joun, A., & Jessup, J. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0650 · Cited by 24
“Earlier,Mcl-1 has been identified as a translational regulated genetic determinant of mTORC1-dependent survival in cancer cells and the extent by which rapamycin modulates expression of Mcl-1 as an important feature of the rapamycin response (26).”
BackgroundHerzog, L.-O., Walters, B., Buono, R., Lee, J. S., Mallya, S., Fung, A., Chiu, H., Nguyen, N., Li, B., Pinkerton, A. B., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01205-9 · Cited by 21
Tuberous sclerosis complex is required for tumor maintenance in MYC‐driven Burkitt's lymphoma
Hartleben, G., Müller, C., Krämer, A., Schimmel, H., Zidek, L. M., Dornblut, C., Winkler, R., Eichwald, S., Kortman, G., Kosan, C., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798589 · Cited by 20
Sénéchal, P., Robert, F., Cencic, R., Yanagiya, A., Chu, J., Sonenberg, N., Paquet, M., & Pelletier, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03940-5 · Cited by 20
Self-citationPetsri, K., Thongsom, S., Racha, S., Chamni, S., Jindapol, S., Kaekratoke, N., Zou, H., & Chanvorachote, P. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03727-6 · Cited by 20
“An increase of mTORC1 activation translationally up-regulates anti-apoptotic protein Mcl-1 expression levels [67, 68].”
BackgroundA bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Meng, D., Zhao, X., Yang, Y. C., Navickas, A., Helland, C., Goodarzi, H., Singh, M., & Bandyopadhyay, S. (2023) · Oncogene · doi:10.1038/s41388-023-02737-z · Cited by 21
“MCL1 has previously been reported as a translational target of mTOR [23], however we did not observe changes in MCL1 translation in our ribosome profiling data and did not observe changes in MCL1 through RNA-seq profiling, hence the cause of the reduction of MCL1 remains unknown and could be potentially due to changes…”
BackgroundPassenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer
Bei, Y., Bramé, L., Kirchner, M., Fritsche‐Guenther, R., Kunz, S., Bhattacharya, A., Rusu, M.-C., Gürgen, D., Dubios, F. P. B., Köppke, J. K. C., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1189 · Cited by 20
“Thus, we hypothesized that the α -KG–induced activation of the mTORC1 pathway in cells with DDX1-MYCN coamplification was required to sustain cancer cell viability through mTORC1-dependent cell survival mechanisms (40).”
BackgroundDevelopments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling
Inman, G. J., & Spender, L. C. (2014) · Cancer Management and Research · doi:10.2147/cmar.s37745 · Cited by 38
Dolgikh, N., Hugle, M., Vogler, M., & Fulda, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1737 · Cited by 23
Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review
Liang, X.-W., Liu, B., Chen, J.-C., Cao, Z. W., Chu, F.-R., Xiong, L., Wang, S.-Z., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177466 · Cited by 20
“Frontiers in Oncology 06 DTCs can reduce cytotoxicity and prevent DNA damage and cell death through increasing the activity of aldehyde dehydrogenase (ALDH) and overcoming the accumulation of toxic intermediates, aldehydes (98).”
BackgroundNogami, A., Okada, K., Ishida, S., Akiyama, H., Umezawa, Y., & Miura, O. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.001 · Cited by 19
Sulkshane, P., & Teni, T. R. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00083 · Cited by 22
“For enhanced biosynthesis of Mcl-1 protein, tumor cells rely on chromosomal alterations that allow increased transcription of the Mcl-1 gene such as through increased accessibility of its promoter [22], increased gene dosage through chromosomal translocation events that involve the Mcl-1 gene [23, 24], enhanced transl…”
BackgroundCombined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
Andersen, N. J., BOGUSLAWSKI, E. B., Kuk, C. C., Chambers, C. M., & Duesbery, N. S. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2989 · Cited by 21
“MCL-1 is cooperatively regulated by MEK and mTOR in the MEK driven OCM1A melanoma cell line (33), and mTOR is known to induce cell survival through upregulation of MCL-1 protein (37).”
BackgroundOh, Y., Jung, H. R., Min, S., Kang, J., Jang, D., Shin, S., Kim, J., Lee, S. E., Sung, C. O., Lee, W., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.018 · Cited by 17
Huang, S.-W., Chang, C.-C., Lin, C.-C., Tsai, J., Chen, Y.-J., Wu, C.-Y., Liu, K.-T., & Shieh, J. (2012) · Journal of dermatological science (Amsterdam) · doi:10.1016/j.jdermsci.2011.11.001 · Cited by 16
“induce apoptosis by inhibiting the translation of Mcl-1 due to mTOR inhibition [45].”
BackgroundResultSelf-citationNOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Dastur, A., Choi, A., Costa, C., Yin, X., Williams, A. F., McClanaghan, J., Greenberg, M., Roderick, J. E., Patel, N. U., Boisvert, J. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0867 · Cited by 18
“Consistent with previous findings (31, 32), mTORC1 suppression is accompanied by lowering of MCL-1 protein levels.”
ResultDembitz, V., Lalić, H., Ostojić, A., Vrḫovac, R., Banfíƈ, H., & Višnjić, D. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1776-2 · Cited by 19
“The expression of Mcl-1 has previously been reported to decrease as a downstream effect of mTOR inhibition [25].”
BackgroundJin, L., Tabe, Y., Kojima, K., Shikami, M., Benito, J., Ruvolo, V. R., Wang, R. Y., McQueen, T. J., Ciurea, S. O., Miida, T., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1076-3 · Cited by 16
“Glycogen synthase kinase-3 (GSK-3), a downstream target of PI3K/ Akt signaling that is inactivated by Akt, is associated with the destabilization of Mcl-1 [31], and mTOR is known to positively control Mcl-1 translation [32].”
Wang, W., Chien, T.-H., Fan, S. M., Huang, W., Lai, S., Wu, J., & Lin, S. (2017) · Radiation Research · doi:10.1667/rr14830.1 · Cited by 16
The androgen receptor mediates antiapoptotic function in myometrial cells
Li, H., Li, Y., Morin, D., Plymate, S. R., Lye, S. J., & Dong, X. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.303 · Cited by 16
“transcriptional and posttranslational levels, Akt can trigger its downstream mTOR pathway to enhance Mcl-1 protein translation.(30,31) Akt can also enhance Mcl-1 protein stability through modulating phosphorylation of GSK3.”
BackgroundModulation of Tumor Tolerance in Primary Central Nervous System Malignancies
Johnson, T. S., Munn, D. H., & Maria, B. L. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/937253 · Cited by 15
“Malignant transformation occurs when a critical mass of genomic and epigenetic mutations leads to uncontrolled cell division, either dominated by a loss of cell cycle control [90–93] or by a defect in apoptotic pathways [92, 94–96].”
Liu, G., Wang, R., Wang, Y., Li, P., Zhao, G., Zhao, L., & Jing, Y. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1224 · Cited by 15
Zucal, C., D’Agostino, V., Casini, A., Mantelli, B., Thongon, N., Soncini, D., Caffa, I., Cea, M., Ballestrero, A., Quattrone, A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1845-1 · Cited by 17
“Previous studies have shown that inhibition of the MTOR/4EBP1 pathway in leukemia cells leads to a reduction in the levels of the anti-apoptotic protein MCL1, with important implications for chemosensitivity [45].”
BackgroundONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
Farmaki, E., Nath, A., Emond, R., Karimi, K. L., Grolmusz, V. K., Cosgrove, P. A., & Bild, A. (2023) · eLife · doi:10.7554/elife.85898 · Cited by 16
“In line with this assumption, mTOR inhibitors are known to induce apoptosis through decreasing expression levels of various anti-apoptotic proteins, including Bcl-2, Bcl-xL, Mcl-1, and survivin ( Du et al., 2018 ; Mills et al., 2008 ; Wangpaichitr et al., 2008 ).”
BackgroundChoi, E., Chung, T., Kim, J., Lee, H., Kwon, K. H., Cho, N., & Cho, S. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-28 · Cited by 14
“(25,26) In this study, we investigated how Mith regulated Mcl-1 protein to induce apoptosis and what the downstream targets of Mcl-1 were in PC3 and DU145 human androgen-independent prostate cancer cell lines and tumor tissues from athymic nude mice xenografts.”
Kuwatsuka, Y., Minami, M., Minami, Y., Sugimoto, K., Hayakawa, F., Miyata, Y., Abe, A., Goff, D. J., Kiyoi, H., & Naoe, T. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.16 · Cited by 14
Du, Y., Long, Q., Shi, Y. Q., Liu, X., Li, X., Zeng, J., Gong, Y., Li, L., Wang, X., & He, D. (2015) · Oncology Reports · doi:10.3892/or.2015.4201 · Cited by 14
“mTOR activity can be suppressed upon energy deprivation, as depleted ATP levels trigger AMPK activation (26).”
Narayan, S., Raza, A., Mahmud, I., Koo, N., Garrett, T. J., Law, M. E., Law, B. K., & Sharma, A. K. (2021) · iScience · doi:10.1016/j.isci.2022.104518 · Cited by 17
“The global inhibition of translation may preferentially affect cancer cells because the cancer cells have higher rates of translation than normal cells (Heys et al., 1991; Mills et al., 2008).”
Background
Metadata
- Authors
- Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., Kogan, S. C., Nadon, R., Housman, D. E., Lowe, S. W., & Pelletier, J.
- Affiliations
- *Department of Biochemistry,
- Cold Spring Harbor Laboratory (US)
- Memorial Sloan Kettering Cancer Center (US)
- Molecular Oncology Research Institute, 750 Washington Street, Tufts–New England Medical Center, Box 5609, Boston, MA 02111;
- Tufts University (US)
- University of California, San Francisco (US)
- McGill University and Génome Québec Innovation Centre (CA)
- Massachusetts Institute of Technology (US)
- Howard Hughes Medical Institute (US)
- McGill University (CA)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10853-10858
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504845
- OpenAlex
- W2024841712
- Cited by
- 285
- References
- 29
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 6 · 2023: 13 · 2022: 19 · 2021: 14 · 2020: 15 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 30 · 2014: 16 · 2013: 24 · 2012: 17
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- Brigham and Women's Hospital
- Canadian Breast Cancer Research Alliance
- National Institutes of Health (CA87497)
- Canadian Institutes of Health Research
- National Cancer Institute (CA-87497, P01CA087497, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTORC1, Mcl-1, translational regulation, TSC2, PI3K/Akt signaling, rapamycin, apoptosis, Eμ-Myc lymphoma, chemosensitivity, mTORC1 inhibitors, Bcl-2 family proteins, tumor cell survival
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Tuberous Sclerosis Complex 2 Protein, Animals, Lymphoma, Proteins, Transcription Factors, Immunoblotting, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-bcl-2, Sirolimus, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Multiprotein Complexes, Immunoprecipitation, Mice, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.